WILMINGTON – Catalyst Clinical Research has acquired its third company, this time, looking to open its growth in the European market.
The clinical development organization, a portfolio company of NovaQuest Capital Management, LLC, announced in a statement today that it has acquired Aptus Clinical, an England-headquartered clinical contract research organization.
According to the company’s statement, the combined companies will become “one multi-region clinical research organization with an accelerated growth trajectory in both the U.S. and Europe.”
Catalyst had previously acquired Triangle Biostatistics in 2019 and Ce3 in 2020. The acquisition of Aptus Clinical marks the first international acquisition for the company.
Headliners: AskBio, Passport, BioSkyrb, Catalyst Clinical, ABBY, ThermoFisher in the news
Expansion
In acquiring Aptus, Catalyst will inherit the firm’s relationship with the Experimental Cancer Medicine Centre (ECMC) network “to support trial set-up and clinical design input,” according to the statement.
That portfolio serves more than 5,300 cancer patients and will grow by nearly 600 patients concurrent to the acquisition, the company noted.
“We are thrilled to be working with Aptus Clinical to expand our reach in the European market, serving clients around the globe to help develop innovative new therapies, improve patient outcomes and enhance our company’s long-term impact,” said Nick Dyer, CEO of Catalyst Clinical Research, in a statement. “Our complementary service offerings and therapeutic area alignment will improve outcomes for all our clients.”
The companies, once combined, will operate as Catalyst Oncology, according to the statement. “Additional studies outside the Oncology therapeutic area will be delivered under the Catalyst Flex solution and operating models,” the statement reads.
Following the merger and acquisition, the firm will employ more than 800 workers globally. Financial terms of the deal were not disclosed.
“We are proud to partner with Catalyst to strengthen our shared commitment to delivering cutting edge science to patient populations who are in desperate need of new therapies”, said Dr. Steve McConchie, CEO of Aptus Clinical, in a statement. “We firmly believe Aptus Clinical and Catalyst are better together and look forward to combining our decades of experience in developing and delivering high quality clinical trials to support our combined organisation to become a significant global provider of innovative clinical research solutions.”
Raleigh-based NovaQuest hauls in nearly $750M for new investment fund
